News and Press Releases
HeartBeat.bio and biotx.ai Sign License and Technology Access Agreement to Identify Novel Targets in Heart Failure
7 July 2025 -- Vienna, Austria and Berlin, Germany -- HeartBeat.bio AG and biotx.ai GmbH today announced a strategic partnership to identify and validate novel therapeutic targets in heart failure. The collaboration combines biotx.ai’s causal...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 7, 2025
Closed Loop Medicine demonstrates application of digital platform for remote blood pressure and medication monitoring
Study published in JMIR validates the feasibility, use and safety of a digital platform for remote, routine monitoring of blood pressure and medication in hypertension patients Findings support the use...
Category: Biotechnology, Other, Pharmaceutical
Posted: December 17, 2024
Babraham Research Campus Cambridge CB22 3AT United Kingdom
Sapio Sciences Enhances Bioanalysis LIMS and ELN with Advanced Immunogenicity Capabilities
Enhancements support ADA and NAb testing workflows, boosting lab efficiency and regulatory compliance for drug development 15 October 2024 – Maryland, US – Sapio Sciences, the science-aware™ lab informatics platform,...
Category: Biotechnology, Drug Discovery
Posted: October 17, 2024
AzurBio Pharma Launches to Fast-Track European Market Entry for Biopharma Companies with Breakthrough Treatments
1 October 2024 -- Paris, France -- AzurBio Pharma, specializing in bringing innovative pharmaceutical products to European markets and focusing on rare and serious diseases with unmet medical needs, is...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 1, 2024
Newcells Biotech launches high-content and high-throughput imaging suite to advance pre-clinical drug development programmes
Investment in state-of-the-art imaging suite to accelerate data generation with physiologically-relevant in vitro models for deeper insights on drug effects in vivo Launch of advanced lung FMT assay provides extensive...
Category: Drug Discovery
Posted: August 8, 2024
Newcells Biotech, The Biophere, Drayman's Way, newcastle Helix, Newcastle-upon-Tyne, NE4 5BX
Deuterium Depletion Is the Key to Getting a Breakthrough in Cancer Therapy
Two review papers consolidate 30 years of research BUDAPEST, Hungary, July 25, 2024 / Biotech Newswire / -- HYD LLC for Cancer Research and Drug Development (HYD or the Company)...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: July 25, 2024
CatSci Announces Strategic Acquisition of Reach Separations to Offer End-To-End Separation Science Support from Discovery to Manufacture
25 June 2024 - Cardiff, UK - CatSci Ltd, an award-winning innovation partner for medicines development, announces the acquisition of Reach Separations, a specialist chromatography provider for the analysis and purification...
Category: BioManufacturing, Pharmaceutical
Posted: June 25, 2024
Bio-Rad Extends Range of Anti-Biotherapeutic Antibodies to Accelerate Antibody Drug Development
Four New Anti-Idiotypic Antibodies and a New Anti-MMAE Antibody Range Support Bioanalytical Assay Development for Preclinical Research and Clinical Trials June 24 2024, California, US, -Bio-Rad Laboratories, Inc. (NYSE: BIO...
Category: BioManufacturing, Clinical Trials, Drug Discovery
Posted: June 24, 2024
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
Enterprise Therapeutics publishes preclinical profile of ETD001, a novel inhaled ENaC blocker
Low doses of ETD001 demonstrate exceptionally long duration of action in sheep model of airway mucus clearance Report in Journal of Cystic Fibrosis discloses best-in-class profile of ETD001 ETD001 scheduled...
Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: June 12, 2024
Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK
Altasciences Receives 2024 CRO Leadership Award for Capabilities
16 May 2024 -- Laval, Québec, Canada -- Altasciences announced today that it has been recognised for excellence in contract research with a 2024 CRO Leadership Award for Capabilities. This...
Category: BioManufacturing, Clinical Trials, Pharmaceutical
Posted: June 3, 2024
Scottish Medicines Consortium (SMC) accepts Camzyos▼(mavacamten) for use on the NHS as an adjunct treatment option for adults with symptomatic obstructive hypertrophic cardiomyopathy
Mavacamten has been accepted for use within NHS Scotland for the treatment of symptomatic(New York Heart Association, NYHA, class II to III) obstructive hypertrophic cardiomyopathy(HCM) in adult patients. HCM is...
Category: Pharmaceutical
Posted: April 8, 2024
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
TMC Pharma champions holistic approach to medical services in rare disease drug development
13 March 2024 – In a recent webinar, rare disease specialist and global clinical research organisation (CRO) TMC Pharma gathered esteemed speakers to share insights into the scope of medical...
Category: Drug Discovery, Pharmaceutical
Posted: March 13, 2024
Lodge Farm Barn Elvetham Park Estate, Fleet Road, Hartley Wintney, Hampshire RG27 8AS, UK
Almost half of Brits think the Government is doing too little to encourage development of new medicines in the UK
25 January -- London, UK -- Recent YouGov polling commissioned by clinical trials start-up Lindus Health has found that 47% of Brits want the Government to be doing more to...
Category: Pharmaceutical
Posted: January 25, 2024
Scottish Medicines Consortium accepts Sotyktu(deucravacitinib) for NHS use in certain adults with moderate to severe plaque psoriasis
Deucravacitinib has been accepted by the Scottish Medicines Consortium (SMC) for use in Scotland for the treatment of adults with moderate to severe plaque psoriasis who are eligible for systemic...
Category: Pharmaceutical
Posted: December 11, 2023
ARC Uxbridge Sanderson Road New Denham Denham Buckinghamshire UB8 1DH
Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Use in Preclinical and Clinical Drug Development
Range of Highly Selective Anti-Idiotypic Antibodies Now Includes Six Antibodies Specific to Dupilumab and its Biosimilars for Bioanalysis and Drug Monitoring 5 October 2023 -- California, US -- Bio-Rad Laboratories,...
Category: Drug Discovery
Posted: October 5, 2023
Bio-Rad Laboratories Ltd. The Junction Station Road Watford Hertfordshire WD17 1ET
